Last reviewed · How we verify
GSK Bio's Influenza Vaccine GSK576389A
GSK Bio's Influenza Vaccine GSK576389A is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development.
At a glance
| Generic name | GSK Bio's Influenza Vaccine GSK576389A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over (PHASE2)
- Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults (PHASE2)
- Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults (PHASE2)
- Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK Bio's Influenza Vaccine GSK576389A CI brief — competitive landscape report
- GSK Bio's Influenza Vaccine GSK576389A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK Bio's Influenza Vaccine GSK576389A
What is GSK Bio's Influenza Vaccine GSK576389A?
GSK Bio's Influenza Vaccine GSK576389A is a Biologic drug developed by GlaxoSmithKline.
Who makes GSK Bio's Influenza Vaccine GSK576389A?
GSK Bio's Influenza Vaccine GSK576389A is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is GSK Bio's Influenza Vaccine GSK576389A in?
GSK Bio's Influenza Vaccine GSK576389A is in Phase 2.